-FDA News
06/11/2008- In his blog, Derek Lowe considers possible reasons for GlaxoSmithKline’s major cuts in its research staff.
Lowe says it seems somewhat paradoxical that the company has been making major acquisitions lately yet is making substantial cuts in its workforce both domestically and abroad.
Lowe provides several theories on why the company is making the cuts, including the company’s recent safety issues with its diabetes drug, Avandia.
“The proximate cause of all this turmoil is probably the loss of all that Avandia revenue, although that may have just advanced the timetable on some decisions that the company was going to make eventually no matter what,” Lowe writes.